Creatinine kinase isoenzyme–MB: A simple prognostic biomarker in patients with pulmonary embolism treated with thrombolytic therapy

Bozbay, Mehmet; Uyarel, Hüseyin; Avşar, Şahin; Öz, Ahmet; Keskin, Muhammed; Tanık, Veysel Ozan; Bakhshaliyev, Nijad; Uğur, Murat; Pehlivanoğlu, Seçkin; Eren, Mehmet

doi:10.1016/j.jcrc.2015.07.014

Cited by 10 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include myocarditis [ 19 ], pulmonary embolism [ 20 , 21 ], cardiac trauma [ 22 ], heart transplantation [ 23 ], chemotherapy-induced cardiotoxicity [ 24 ], and cardiac surgery [ 25 ]. However, CK-MB levels in these diseases/conditions do not add significant value to their diagnosis or the prognosis, and often cause confusion in the interpretation of the results [ 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. Moreover, increased CK-MB levels do not specify the underlying etiology, and false-positive results can occur in a number of non-cardiovascular conditions, including end-stage renal failure [ 28 ], skeletal muscle trauma [ 22 ], muscular dystrophy [ 29 ], dermatomyositis [ 30 ], rhabdomyolysis [ 31 ], delirium tremens [ 32 ], and amyloidosis [ 33 ].…”

Section: Historic Overview: Early Biomarkers For Cvdsmentioning

confidence: 99%

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Omran

Kyrou

Osman

et al. 2022

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a major healthcare burden on the population worldwide. Early detection of this disease is important in prevention and treatment to minimise morbidity and mortality. Biomarkers are a critical tool to either diagnose, screen, or provide prognostic information for pathological conditions. This review discusses the historical cardiac biomarkers used to detect these conditions, discussing their application and their limitations. Identification of new biomarkers have since replaced these and are now in use in routine clinical practice, but still do not detect all disease. Future cardiac biomarkers are showing promise in early studies, but further studies are required to show their value in improving detection of CVD above the current biomarkers. Additionally, the analytical platforms that would allow them to be adopted in healthcare are yet to be established. There is also the need to identify whether these biomarkers can be used for diagnostic, prognostic, or screening purposes, which will impact their implementation in routine clinical practice.

show abstract

Section: Historic Overview: Early Biomarkers For Cvdsmentioning

confidence: 99%

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Omran

Kyrou

Osman

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Creatinine kinase isoenzyme–MB and N -terminal pro-B-type natriuretic peptide were reported as prognostic laboratory biomarkers in PE. 3 In addition, recent operation or fracture, shock during hospitalization, and mechanical ventilation were also defined as prognostic factors. 4 The recent PE guideline insistently suggests Pulmonary Embolism Severity Index (PESI) to estimate long-term survival.…”

Section: Introductionmentioning

confidence: 99%

A Novel Independent Survival Predictor in Pulmonary Embolism: Prognostic Nutritional Index

Hayıroğlu

Keskin

et al. 2017

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

The prognostic impact of nutritional status in patients with pulmonary embolism (PE) is poorly understood. A well-accepted nutritional status parameter, prognostic nutritional index (PNI), which was first demonstrated to be valuable in patients with cancer and gastrointestinal surgery, was introduced to patients with PE. Our aim was to evaluate the predictive value of PNI in outcomes of patients with PE. We evaluated the in-hospital and long-term (53.8 ± 5.4 months) prognostic impact of PNI on 251 patients with PE. During a median follow-up of 53.8 ± 5.4 months, 27 (11.6%) patients died in hospital course and 31 (13.4%) died in out-of-hospital course. The patients with lower PNI had significantly higher in-hospital and long-term mortality. The Cox proportional hazard analyses showed that PNI was associated with an increased risk of all-cause death for both unadjusted model and adjusted for all covariates. Our study demonstrated that PNI, calculated based on serum albumin level and lymphocyte count, is an independent prognostic factor for mortality in patients with PE.

show abstract

“…A signi cant discriminatory ability was found for both increased total CPK levels and decreased CPK-MB relative ratios for the diagnosis of ectopic pregnancy [16] . Additionally, Mehmet Bozbay et al found that pulmonary embolism patients with high CK-MB levels (> 31.5 U/L) had a higher in-hospital mortality after treatment with thrombolytic therapy; a CK-MB level of higher than 31.5 U/L had a sensitivity of 86.7% and speci city of 83.5% for predicting in-hospital mortality [17] . Another study found a signi cant association between serum CK-MB and the severity of disease among children with RV-infected gastroenteritis [18] .…”

Section: Discussionmentioning

confidence: 99%

Clinical prognostic value of elevated CK-MB in severe multiple trauma patients with nonmyocardial contusion

Huang

Sun

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Unintentional injury was the leading cause of death and disability among individuals younger than 49 years globally in 2019. However, the association between serum CK-MB levels and clinical value in polytrauma patients with nonmyocardial contusion remains unclear. Methods: This was a single-center, retrospective study. Demographic and clinical data were extracted from the Hospital Information System (HIS) at the Third Xiangya Hospital of Central South University. A total of 287 patients were included in the study. Patients were divided into a normal group (CK-MB ≤25 U/L) and an abnormal group (CK-MB >25 U/L) based on a low CK-MB level. Further clinical and follow- up data were analyzed by using univariate and multivariate logistic regression.Finally, disease-free survival and overall survival were calculated by the Kaplan– Meier method. Results: Multivariate logistic regression demonstrated that CK-MB (OR: 1.023, 95% CI: 1.006-1.040) was an independent risk factor for predicting in-hospital mortality in polytrauma patients with nonmyocardial contusion. Compared with normal CK-MB levels, CK-MB elevation was associated with a longer length of ICU stay (7.38±13.13 vs. 3.16±5.86 days, P =0.004) and total length of hospital stay (24.73±23.04 vs. 18.29±14.63 days, P =0.015) and was more likely to result in arrhythmia during hospitalization (19.29% vs. 10%, P =0.048). Moreover, the follow-up data showed that patients with CK-MB elevation were more likely to have cardiopalmus after discharge (15.00% vs. 5.68%, P =0.027). Conclusion: Our findings suggested that elevated CK-MB played an important role in the prognosis of polytrauma patients with nonmyocardial contusion, and a higher level of CK-MB indicated a poor prognosis.

show abstract

Creatinine kinase isoenzyme–MB: A simple prognostic biomarker in patients with pulmonary embolism treated with thrombolytic therapy

Cited by 10 publications

References 32 publications

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

A Novel Independent Survival Predictor in Pulmonary Embolism: Prognostic Nutritional Index

Clinical prognostic value of elevated CK-MB in severe multiple trauma patients with nonmyocardial contusion

Contact Info

Product

Resources

About